Kalaris insider group buys 244,300 shares
Kalaris Therapeutics, Inc. reported an insider group transaction where an affiliated investment vehicle, Samsara Opportunity Fund, L.P., bought 244,300 shares of common stock at $4.83 per share in a privately negotiated deal with Samsara BioCapital, L.P.
Rhea-AI Filing Summary
Kalaris Therapeutics, Inc. reported an insider group transaction where an affiliated investment vehicle, Samsara Opportunity Fund, L.P., bought 244,300 shares of common stock at $4.83 per share in a privately negotiated deal with Samsara BioCapital, L.P.
The filing also records several non-market, pro rata in-kind distributions among related Samsara entities, reallocating a total of 86,314 shares of Kalaris common stock internally. Following the purchase, Samsara Opportunity Fund, L.P. holds 2,224,147 Kalaris shares indirectly associated with director and ten percent owner Dr. Srinivas Akkaraju.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 244,300 shares
Net Buy
4 txns
Insider
AKKARAJU SRINIVAS, Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC
Role
Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought
244,300 shs ($1.18M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 244,300 | $4.83 | $1.18M |
| Other | Common Stock | 66,906 | $0.00 | $0.00 |
| Other | Common Stock | 14,937 | $0.00 | $0.00 |
| Other | Common Stock | 4,471 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 2,224,147 shares (Indirect, By Samsara Opportunity Fund, L.P.);
Common Stock — 10,657,028 shares (Indirect, By Samsara BioCapital, L.P.);
Common Stock — 14,937 shares (Indirect, By Samsara BioCapital GP, LLC);
Common Stock — 19,408 shares (Indirect, By Samsara BioCapital Partners, L.P.)
Footnotes (8)
- F1. Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.
- F2. Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein.
- F3. Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners.
- F4. The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest.
- F5. Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
- F6. Represents receipt of shares in the distribution in kind described in footnote (3).
- F7. Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
- F8. Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
Key Figures
Insider purchase size: 244,300 shares
Purchase price: $4.83 per share
Post-transaction holdings: 2,224,147 shares
+3 more
6 metrics
Insider purchase size
244,300 shares
Common stock bought by Samsara Opportunity Fund, L.P.
Purchase price
$4.83 per share
Privately negotiated transaction with Samsara BioCapital, L.P.
Post-transaction holdings
2,224,147 shares
Kalaris common stock held by Samsara Opportunity Fund, L.P.
Restructuring-related shares
86,314 shares
Pro rata, in-kind distributions among Samsara entities
Shares distributed to Samsara GP LLC
14,937 shares
Received in in-kind distribution from Samsara BioCapital, L.P.
Shares distributed to Samsara BioCapital Partners
4,471 shares
Received in in-kind distribution from Samsara BioCapital, L.P.
Key Terms
open-market purchase, privately negotiated transaction, pro rata, in-kind distribution, beneficially own, +1 more
5 terms
open-market purchase financial
"Purchase in open market or private transaction"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
privately negotiated transaction financial
"purchase of shares from Samsara BioCapital, L.P. in a privately negotiated transaction"
A privately negotiated transaction is a deal whose terms are worked out directly between a buyer and a seller rather than through a public market or open auction. Think of it like selling a car to a neighbor instead of putting it on eBay: the price, timing and conditions are agreed one-on-one, so investors may see less public information, different pricing compared with market trades, and potential impacts on liquidity and valuation.
pro rata, in-kind distribution financial
"Represents a pro rata, in-kind distribution, without additional consideration"
beneficially own financial
"may be deemed to beneficially own the securities held by Samsara Opportunity Fund"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pecuniary interest financial
"disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Kalaris Therapeutics (KLRS) report in this Form 4?
Kalaris Therapeutics reported that Samsara Opportunity Fund, L.P., an affiliated entity, bought 244,300 shares of common stock at $4.83 per share. This acquisition came via a privately negotiated transaction with Samsara BioCapital, L.P., increasing the fund’s indirect stake in KLRS.
Was the KLRS insider transaction an open-market trade or a private deal?
The 244,300-share KLRS purchase was executed as a privately negotiated transaction between Samsara Opportunity Fund, L.P. and Samsara BioCapital, L.P. It is coded as a purchase transaction rather than an in-kind distribution or routine administrative transfer among related entities.
What are the pro rata in-kind distributions mentioned in the Kalaris (KLRS) Form 4?
The filing describes a pro rata, in-kind distribution of 86,314 Kalaris shares by Samsara BioCapital, L.P. to its investors and affiliates. These distributions, made without additional consideration, reallocated shares to limited partners, Samsara BioCapital GP, LLC, and Samsara BioCapital Partners, L.P.
AI-generated analysis. How Rhea-AI works. Not financial advice.
